drugset / Trial / NCT00056095

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

NCT00056095

Phase 2 Completed 57 enrolled UNICANCER
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well allogeneic stem cell transplant works in treating patients with metastatic kidney cancer.

Timeline

Start
2002-11-04
Primary completion
2008-02-13
Completion
2016-08-17

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclophosphamide Other / unclassified Intravenous
Background Cyclosporine Peptide
Background Fludarabine Small molecule Intravenous
Background therapeutic allogeneic lymphocytes Cell therapy

Indications